|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123258 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-23 10:28:51 |
|
注册时间: Date of Registration: |
2026-04-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于脑机接口的正念冥想改善慢性耳鸣临床症状的多中心随机对照研究 |
|
Public title: |
A Multicenter Randomized Controlled Trial Evaluating the Efficacy of Brain-Computer Interface-Based Mindfulness Meditation on Clinical Symptoms in Patients with Chronic Tinnitus |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑机接口正念冥想干预/缓解耳鸣症状的研究 |
|
Scientific title: |
A Study on Brain-Computer Interface (BCI)-Based Mindfulness Meditation for the Intervention and Alleviation of Tinnitus Symptoms |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黎志成 |
研究负责人: |
曾祥丽 |
|
Applicant: |
Li Zhicheng |
Study leader: |
Zeng Xiangli |
|
申请注册联系人电话: Applicant telephone: |
+86 20 8217 9215 |
研究负责人电话: Study leader's telephone: |
+86 20 8217 9215 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lzhcheng@mail.sysu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
zxiangl@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市开创大道2693号 |
研究负责人通讯地址: |
广州市开创大道2693号 |
|
Applicant address: |
No. 2693 Kaichuang Avenue, Guangzhou City, Guangdong Province, P.R.China |
Study leader's address: |
No. 2693 Kaichuang Avenue, Guangzhou City, Guangdong Province, P.R.China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第三医院 |
||
|
Applicant's institution: |
The Third Affiliated Hospital of Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学附属第三医院 |
||
|
Affiliation of the Leader: |
The Third Affiliated Hospital of Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
中大附三医伦 II 2025-303-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第三医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-05 00:00:00 |
||
|
伦理委员会联系人: |
黄凯琪 |
||
|
Contact Name of the ethic committee: |
Huang Kaiqi |
||
|
伦理委员会联系地址: |
广东省广州市天河路600号 |
||
|
Contact Address of the ethic committee: |
No. 600, Tianhe Road, Guangzhou, Guangdong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8525 3302 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市天河路600号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.600, Tianhe Road, Guangzhou City, Guangdong Province, P.R.China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
This study was self-funded |
||||||||||||||||||||||
|
Target disease: |
tinnitus |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1)探讨脑机接口正念冥想对耳鸣症状的即刻缓解效果(每天干预,每次干预实验后进行疗效评估); 2)探讨脑机接口正念冥想对耳鸣症状缓解的长期效果(对比4周干预前和4周干预后数据进行评估); 3)通过脑电数据分析,探索脑机接口正念冥想缓解减轻耳鸣症状的脑机制(4周干预前后,使用单通道头环+64通道脑电同时采集静息态和正念冥想态脑电)。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To explore the immediate therapeutic effect of Brain-Computer Interface (BCI)-assisted mindfulness meditation intervention on tinnitus symptom alleviation: the intervention will be administered daily, and therapeutic efficacy will be evaluated immediately upon completion of each intervention session. 2. To investigate the long-term sustained therapeutic effect of BCI-assisted mindfulness meditation intervention on tinnitus symptom alleviation: efficacy will be assessed via pairwise comparison of outcome data collected before the initiation and after the completion of the 4-week intervention regimen. 3. To elucidate the cerebral neural mechanisms of BCI-assisted mindfulness meditation in relieving tinnitus symptoms through EEG data analysis: resting-state and mindfulness meditation-state EEG data will be simultaneously collected with a single-channel headband and a 64-channel EEG system at two predefined time points, namely before and after the 4-week intervention. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.耳鸣主诉; 2.报告持续3个月以上的耳鸣; 3.年满18岁及以上,60岁以下; 4.具备常规电子设备使用能力。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. With tinnitus as the primary clinical chief complaint; 2. Self-reported continuous tinnitus that has lasted for 3 months or longer; 3. Aged between 18 and 60 years (inclusive of the 18-year-old lower limit, exclusive of the 60-year-old upper limit); 4. Possess the functional ability to use and operate routine electronic devices independently. |
||||||||||||||||||||||
|
排除标准: |
1.排除传导性耳聋、中耳手术史、血管畸变导致的搏动性耳鸣和梅尼埃病的耳鸣患者; 2.排除头部创伤史、中枢神经系统疾病史、精神性疾病史、药物滥用史; 3.排除严重听损,其他精神类疾病如严重抑郁/精神分裂等, 4.排除肿瘤及其他耳科学疾病如眩晕等; 5.排除同时参与其他临床研究。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Exclude patients with conductive hearing loss, a history of middle ear surgery, pulsatile tinnitus caused by vascular malformations, and tinnitus from Ménière's disease; 2. Exclude those with a history of head trauma, central nervous system diseases, psychiatric disorders, or drug abuse; 3. Exclude severe hearing loss and other psychiatric disorders such as severe depression or schizophrenia; 4. Exclude tumors and other otological diseases such as vertigo; 5. Exclude those simultaneously participating in other clinical studies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2028-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-07-01 00:00:00 至 To 2028-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本临床研究将采用区组随机化法对参与者进行随机分组,在研究期间通过双盲的方法,对参与者、参与疗效与安全性评判的研究人员保持盲态,减少相关偏倚。由统计专家对纳入研究的参与者进行1:1随机化分组。统计专家将用电脑生成的随机数表对参与者进行编号,随后按编号大小顺序进行排列,依次将参与者随机划分入长度为2或4的随机区组中,完成随机化。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This clinical study will adopt block randomization to perform random allocation of participants. A double-blinding approach will be implemented throughout the study period, and blinding will be maintained for participants, as well as study researchers responsible for efficacy and safety evaluation, to reduce the risk of relevant bias. An independent biostatistician will conduct 1:1 randomization of eligible participants enrolled in the study. The biostatistician will assign unique identification numbers to participants via a computer-generated random number table, sort the numbers in ascending order, and sequentially and randomly assign participants to random blocks with block sizes of 2 and 4 to finalize the randomization process. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对参与者、参与疗效与安全性评判的研究人员保持盲态 |
|
Blinding: |
Blinding will be maintained for participants, as well as study researchers responsible for efficacy and safety evaluation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表采集及管理数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All study-related data shall be collected, documented and managed using pre-specified standardized Case Report Forms (CRFs) during the entire study period. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |